Key Takeaways
- • A study presented at the 2026 ATS International Conference demonstrates that patients with pneumonia treated at private equity-owned hospitals experience significantly higher in-hospital mortality rates compared to patients at non-PE hospitals.
- • COPD patients at PE-owned hospitals show elevated 30-day hospital readmission rates, a key quality metric tied to reimbursement penalties and patient outcomes across the healthcare sector.
- • The research analyzed over 341,800 patient encounters (146,900 COPD cases and 194,900 pneumonia cases) using matched control groups, making this the first disease-specific analysis linking PE acquisition to worse outcomes in pulmonary conditions.
- • Prior studies documented PE-related deterioration in broader quality measures including higher rates of hospital-acquired infections and adverse events, but this is the first to isolate COPD and pneumonia—the leading lung-related admission diagnoses.
- • Dr. Stephen Mein of Beth Israel Deaconess Medical Center calls for stronger regulatory oversight of PE healthcare acquisitions, signaling potential policy implications as PE acquisition of hospital systems accelerates across the U.S.
Summary
A comprehensive study presented at the 2026 American Thoracic Society International Conference reveals material deterioration in patient outcomes at hospitals acquired by private equity firms, particularly for two high-volume respiratory conditions. Researchers documented higher in-hospital mortality rates among pneumonia patients and elevated 30-day readmission rates for COPD patients at PE-owned facilities compared to matched non-PE hospitals.
The study analyzed clinical data from 146,900 COPD encounters and 194,900 pneumonia hospitalizations at private equity-owned hospitals, using control-group matching methodology to isolate the acquisition effect. This represents the first disease-specific examination of how PE ownership correlates with outcomes in COPD and pneumonia—the most prevalent lung-related causes of hospital admission. The researchers controlled for patient populations and facility characteristics to strengthen causal inference.
The findings extend a growing body of evidence documenting quality degradation following PE acquisition. Earlier research established elevated rates of hospital-acquired adverse events, including falls and bloodstream infections, as well as patient-reported deterioration in care experiences. However, this study provides the first concrete linkage between PE ownership and specific clinical outcomes in pulmonary disease management, a significant distinction for institutional investors and healthcare stakeholders evaluating acquisition impact.
Dr. Stephen Mein, first author and pulmonologist at Beth Israel Deaconess Medical Center's Richard A. and Susan F. Smith Center for Outcomes Research, emphasized regulatory implications: "Our findings add to growing concerns around the detrimental effects of private equity in health care and highlight a critical need for stronger regulations of these acquisitions to protect our patients." The statement signals potential policy headwinds as PE acquisition of hospital systems accelerates—a trend that directly impacts valuations, deal structures, and exit multiples in healthcare PE portfolios.
The study analyzed clinical data from 146,900 COPD encounters and 194,900 pneumonia hospitalizations at private equity-owned hospitals, using control-group matching methodology to isolate the acquisition effect. This represents the first disease-specific examination of how PE ownership correlates with outcomes in COPD and pneumonia—the most prevalent lung-related causes of hospital admission. The researchers controlled for patient populations and facility characteristics to strengthen causal inference.
The findings extend a growing body of evidence documenting quality degradation following PE acquisition. Earlier research established elevated rates of hospital-acquired adverse events, including falls and bloodstream infections, as well as patient-reported deterioration in care experiences. However, this study provides the first concrete linkage between PE ownership and specific clinical outcomes in pulmonary disease management, a significant distinction for institutional investors and healthcare stakeholders evaluating acquisition impact.
Dr. Stephen Mein, first author and pulmonologist at Beth Israel Deaconess Medical Center's Richard A. and Susan F. Smith Center for Outcomes Research, emphasized regulatory implications: "Our findings add to growing concerns around the detrimental effects of private equity in health care and highlight a critical need for stronger regulations of these acquisitions to protect our patients." The statement signals potential policy headwinds as PE acquisition of hospital systems accelerates—a trend that directly impacts valuations, deal structures, and exit multiples in healthcare PE portfolios.
Go deeper than the headline
Research every firm in this story, track the ones that matter and get the daily briefing — free for 7 days.